381 related articles for article (PubMed ID: 17299090)
1. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
Spisek R; Charalambous A; Mazumder A; Vesole DH; Jagannath S; Dhodapkar MV
Blood; 2007 Jun; 109(11):4839-45. PubMed ID: 17299090
[TBL] [Abstract][Full Text] [Related]
2. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.
Neznanov N; Komarov AP; Neznanova L; Stanhope-Baker P; Gudkov AV
Oncotarget; 2011 Mar; 2(3):209-21. PubMed ID: 21444945
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity.
Mimnaugh EG; Xu W; Vos M; Yuan X; Isaacs JS; Bisht KS; Gius D; Neckers L
Mol Cancer Ther; 2004 May; 3(5):551-66. PubMed ID: 15141013
[TBL] [Abstract][Full Text] [Related]
4. Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.
Moeller I; Spagnoli GC; Finke J; Veelken H; Houet L
Cancer Immunol Immunother; 2012 Nov; 61(11):2079-90. PubMed ID: 22562379
[TBL] [Abstract][Full Text] [Related]
5. Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells.
Spisek R; Dhodapkar MV
Cell Cycle; 2007 Aug; 6(16):1962-5. PubMed ID: 17721082
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro.
Jung SH; Lee YK; Lee HJ; Choi NR; Vo MC; Hoang MD; Lim MS; Nguyen-Pham TN; Kim HJ; Lee JJ
Exp Hematol; 2014 Apr; 42(4):274-81. PubMed ID: 24407159
[TBL] [Abstract][Full Text] [Related]
7. Antimyeloma activity of heat shock protein-90 inhibition.
Mitsiades CS; Mitsiades NS; McMullan CJ; Poulaki V; Kung AL; Davies FE; Morgan G; Akiyama M; Shringarpure R; Munshi NC; Richardson PG; Hideshima T; Chauhan D; Gu X; Bailey C; Joseph M; Libermann TA; Rosen NS; Anderson KC
Blood; 2006 Feb; 107(3):1092-100. PubMed ID: 16234364
[TBL] [Abstract][Full Text] [Related]
8. Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro.
Peron M; Bonvini P; Rosolen A
BMC Cancer; 2012 Jun; 12():233. PubMed ID: 22691173
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.
Straube C; Wehner R; Wendisch M; Bornhäuser M; Bachmann M; Rieber EP; Schmitz M
Leukemia; 2007 Jul; 21(7):1464-71. PubMed ID: 17495970
[TBL] [Abstract][Full Text] [Related]
10. Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
Mujtaba T; Kanwar J; Wan SB; Chan TH; Dou QP
Int J Mol Med; 2012 Jan; 29(1):102-6. PubMed ID: 22012631
[TBL] [Abstract][Full Text] [Related]
11. Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91.
Cirone M; Di Renzo L; Lotti LV; Conte V; Trivedi P; Santarelli R; Gonnella R; Frati L; Faggioni A
PLoS One; 2012; 7(3):e31732. PubMed ID: 22412839
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
[TBL] [Abstract][Full Text] [Related]
13. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC
Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546
[TBL] [Abstract][Full Text] [Related]
14. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model.
Siveen KS; Mustafa N; Li F; Kannaiyan R; Ahn KS; Kumar AP; Chng WJ; Sethi G
Oncotarget; 2014 Feb; 5(3):634-48. PubMed ID: 24504138
[TBL] [Abstract][Full Text] [Related]
15. Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications.
Neznanov N; Gorbachev AV; Neznanova L; Komarov AP; Gurova KV; Gasparian AV; Banerjee AK; Almasan A; Fairchild RL; Gudkov AV
Cell Cycle; 2009 Dec; 8(23):3960-70. PubMed ID: 19901558
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
17. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.
Khong T; Spencer A
Mol Cancer Ther; 2011 Oct; 10(10):1909-17. PubMed ID: 21859842
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
Suzuki R; Hideshima T; Mimura N; Minami J; Ohguchi H; Kikuchi S; Yoshida Y; Gorgun G; Cirstea D; Cottini F; Jakubikova J; Tai YT; Chauhan D; Richardson PG; Munshi NC; Utsugi T; Anderson KC
Leukemia; 2015 Feb; 29(2):510-4. PubMed ID: 25306900
[No Abstract] [Full Text] [Related]
19. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
Neri P; Ren L; Gratton K; Stebner E; Johnson J; Klimowicz A; Duggan P; Tassone P; Mansoor A; Stewart DA; Lonial S; Boise LH; Bahlis NJ
Blood; 2011 Dec; 118(24):6368-79. PubMed ID: 21917757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
